Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type

• Main Authors: Elena Maccaroni (Author), Edoardo Lenci (Author), Veronica Agostinelli (Author), Valeria Cognigni (Author), Riccardo Giampieri (Author), Paola Mazzanti (Author), Marzia Di Pietro Paolo (Author), Francesca Bianchi (Author), Cristiana Brugiati (Author), Laura Belvederesi (Author), Silvia Pagliaretta (Author), Alessandra Mandolesi (Author), Marina Scarpelli (Author), Alberto Murrone (Author), Francesca Morgese (Author), Zelmira Ballatore (Author), Rossana Berardi (Author)
• Format: Book
• Published: Open Exploration Publishing Inc., 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline alterations in mismatch repair (MMR) genes leading to increased risk of colon cancer as well as other cancer types. Non-small cell lung cancer (NSCLC) is not among typical Lynch syndrome-associated tumors: pembrolizumab...